Alterity Announces Funding from Michael J. Fox Foundation for ATH434 Dose Optimization for Parkinson’s Disease Clinical Trials

Alterity Therapeutics, Ltd. announced the award of a grant from The Michael J. Fox Foundation for Parkinson’s Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson’s disease based on imaging of brain iron.